Leading a transformational approach to cell and gene therapies for diseases of the skin and connective tissue
Fibrocell is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue. The Company is utilizing its proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease. Fibrocell’s pipeline of localized gene therapy candidates include FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a life-threatening genetic disorder diagnosed in infancy with no cure or treatment approved by the U.S. Food and Drug Administration. Fibrocell is also developing FCX-013 for the treatment of moderate to severe localized scleroderma. For more information, visit www.fibrocell.com or follow us on Twitter at @Fibrocell.
Fibrocell Science Second Quarter 2019 Financial Results & Recent Highlights Conference Call & Webcast
Thursday, August 15, 2019 at 8:30 AM EDT
Copyright West LLC. Minimum 15 minutes delayed.